Major Depressive Disorder - Japan Drug Forecast and Market Assessment to 2025 - Product Image

Major Depressive Disorder - Japan Drug Forecast and Market Assessment to 2025

  • ID: 4043111
  • Report
  • Region: Japan
  • 326 pages
  • GlobalData
1 of 3
Major Depressive Disorder - Japan Drug Forecast and Market Assessment to 2025


Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. It is characterized by single or recurrent major depressive episodes (MDEs), where patients can typically experience periods of depressed mood, loss of energy, abnormal cognition, anxiety and suicidal ideation. Similar to other neuropsychiatric disorders, MDD has a multifaceted and varied etiology, and remains poorly understood. The MDD market is crowded and competitive, with more than 30 products available for the treatment of patients, the majority of which are now available as inexpensive generics. The MDD market is therefore in a dynamic phase where patent expiries for historically top-selling products such as Eli Lilly’s Cymbalta and Otsuka/BMS’ Abilify have occurred, and recent launches of Lundbeck/Takeda’s Trintellix and Otsuka/Lundbeck’s Rexulti will be a significant driver of growth in the 7MM. Growth in the MDD market is also expected to be driven by the potential introduction of six promising late-stage pipeline products into the market during the forecast period, all of which are directed towards treatment-resistant patients, a significant unmet need.

The author estimated that MDD drug sales in Japan during 2015 reached $315.0m, making it the second largest single market in the 7MM. The author estimates that the Japanese MDD market will be turbulent during the forecast period with important patent losses occurring, such as Otsuka/BMS’ Abilify, Eli Lilly’s Cymbalta, and Lundbeck/Allergan’s Lexapro. Effexor will see the highest growth rate of any drug in the Japanese MDD market over the 10-year forecast.


- Overview of MDD including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in Japan including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in Japan from 2015-2025.
- Analysis of the impact of key events as well the drivers and restraints affecting Japan MDD market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for MDD.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2015-2025 in Japan.
Note: Product cover images may vary from those shown
2 of 3
1. List of Tables and Figures

2 Introduction

2.1 Related Reports

2.2 Upcoming Related Reports

3 Disease Overview

3.1 Etiology and Pathophysiology

3.1.1 Etiology

3.1.2 Pathophysiology

3.2 Classification

3.3 Symptoms and Subtypes of Major Depressive Disorder

3.4 Prognosis

3.5 Quality of Life

4 Disease Management

4.1 Diagnosis and Treatment Overview

4.1.1 Diagnosis

4.1.2 Treatment Guidelines

4.1.3 Clinical Practice

4.2 Japan

5 Competitive Assessment

5.1 Overview

5.2 Selective Serotonin Reuptake Inhibitors

5.2.1 Lexapro (Escitalopram)

5.2.2 Viibryd (Vilazodone)

5.2.3 Other Selective Serotonin Reuptake Inhibitors

5.3 Serotonin-Norepinephrine Reuptake Inhibitors

5.3.1 Cymbalta (Duloxetine)

5.3.2 Effexor (Venlafaxine)

5.3.3 Fetzima (Levomilnacipran)

5.3.4 Savella (Milnacipran)

5.3.5 Pristiq (Desvenlafaxine)

5.4 Multimodal Antidepressants

5.4.1 Trintellix (Vortioxetine)

5.5 Other Antidepressants

5.5.1 Bupropion

5.5.2 Symbyax (Olanzapine/Fluoxetine)

5.5.3 Mirtazapine

5.5.4 Monoamine Oxidase Inhibitors

5.5.5 Tricyclic Antidepressants

5.6 Antipsychotics

5.6.1 Abilify (Aripiprazole)

5.6.2 Seroquel XR (Quetiapine XR)

5.6.3 Rexulti (Brexpiprazole)

5.7 Other Therapeutic Classes

6 Unmet Need and Opportunity

6.1 Overview

6.2 New Therapies with Better Efficacy

6.2.1 Unmet Need

6.2.2 Gap Analysis

6.2.3 Opportunity

6.3 Improved Safety Profiles

6.3.1 Unmet Need

6.3.2 Gap Analysis

6.3.3 Opportunity

6.4 Rapid Onset of Action

6.4.1 Unmet Need

6.4.2 Gap Analysis

6.4.3 Opportunity

6.5 Personalized Treatment Approach

6.5.1 Unmet Need

6.5.2 Gap Analysis

6.5.3 Opportunity

6.6 Manage Patient Outcome Expectations

6.6.1 Unmet Need

6.6.2 Gap Analysis

6.6.3 Opportunity

7 Pipeline Assessment

7.1 Overview

7.2 Clinical Trial Mapping

7.2.1 Clinical Trials by Class of Therapy

7.3 Promising Drugs in Clinical Development

7.3.1 ALKS-5461

7.3.2 Vraylar (Cariprazine)

7.3.3 ASC-01

7.3.4 AXS-05

7.3.5 Esketamine

7.3.6 Rapastinel (GLYX-13)

7.3.7 Strada (MSI-195)

7.3.8 Viotra (Tramadol)

7.4 Promising Drugs in Early-Stage Development

7.4.1 CGP3466B

7.4.2 NSI-189

7.5 Other Drugs in Development

8 Market Outlook

8.1 Japan

8.1.1 Forecast

8.1.2 Key Events

8.1.3 Drivers and Barriers

9 Appendix

9.1 Bibliography

9.2 Abbreviations

9.3 Methodology

9.4 Forecasting Methodology

9.4.1 Diagnosed NSCLC Patients

9.4.2 Percent Drug-Treated Patients

9.4.3 Drugs Included in Each Therapeutic Class

9.4.4 Launch and Patent Expiry Dates

9.4.5 General Pricing Assumptions

9.4.6 Individual Drug Assumptions

9.4.7 Generic Erosion

9.4.8 Pricing of Pipeline Agents

9.5 Primary Research - KOLs

9.5.1 KOLs

9.6 About the Authors

9.6.1 Analyst

9.6.2 Therapy Area Director

9.6.3 Epidemiologist

9.6.4 Global Head of Healthcare

9.7 About

9.8 Disclaimer

List of Tables

Table 1: Classification and Criteria of MDD (DSM-IV) and MDE (ICD-10)

Table 2: Subtypes of Major Depressive Disorder

Table 3: Severity of Depressive Episodes According to ICD-10 and DSM-IV Diagnostic Criteria

Table 4: Treatment Guidelines for Major Depressive Disorder

Table 5: Most-Prescribed Drugs for MDD by Class in the 7MM, 2015

Table 6: Country Profile - Japan

Table 7: Leading Treatments for MDD, 2016

Table 8: Product Profile - Lexapro

Table 9: Lexapro/Cipralex SWOT Analysis, 2016

Table 10: Product Profile - Viibryd

Table 11: Summary of Efficacy Results for the Primary Endpoint in Viibryd Clinical Trials

Table 12: Viibryd SWOT Analysis, 2016

Table 13: Summary of SSRIs, 2016

Table 14: SSRIs SWOT Analysis, 2016

Table 15: Product Profile - Cymbalta

Table 16: Cymbalta SWOT Analysis, 2016

Table 17: Product Profile - Effexor

Table 18: Effexor SWOT Analysis, 2016

Table 19: Product Profile - Fetzima

Table 20: Fetzima SWOT Analysis, 2016

Table 21: Product Profile - Savella

Table 22: Savella SWOT Analysis, 2016

Table 23: Product Profile - Pristiq

Table 24: Pristiq SWOT Analysis, 2016

Table 25: Product Profile - Trintellix

Table 26: Trintellix SWOT Analysis, 2016

Table 27: Product Profile - Bupropion

Table 28: Bupropion SWOT Analysis, 2016

Table 29: Product Profile - Symbyax

Table 30: Symbyax SWOT Analysis, 2016

Table 31: Product Profile - Mirtazapine

Table 32: Mirtazapine SWOT Analysis, 2016

Table 33: MAOIs SWOT Analysis, 2016

Table 34: TCAs SWOT Analysis, 2016

Table 35: Product Profile - Abilify

Table 36: Abilify SWOT Analysis, 2016

Table 37: Product Profile - Seroquel XR

Table 38: Seroquel XR SWOT Analysis, 2016

Table 39: Product Profile - Rexulti

Table 40: Rexulti SWOT Analysis, 2016

Table 41: Summary of Minor Therapeutic Classes in MDD, 2016

Table 42: Unmet Needs and Opportunities in MDD

Table 43: Promising Drugs in Clinical Development for MDD, 2016

Table 44: Comparison of Drugs in Development for MDD, 2016

Table 45: Product Profile - ALKS-5461

Table 46: SWOT Analysis - ALKS-5461, 2016

Table 47: Product Profile - Vraylar

Table 48: SWOT Analysis - Vraylar, 2016

Table 49: Product Profile - ASC-01

Table 50: SWOT Analysis - ASC-01, 2016

Table 51: Product Profile - AXS-05

Table 52: SWOT Analysis - AXS-05, 2016

Table 53: Product Profile - Esketamine

Table 54: SWOT Analysis - Esketamine, 2016

Table 55: Product Profile - Rapastinel

Table 56: SWOT Analysis - Rapastinel, 2016

Table 57: Product Profile - Strada

Table 58: SWOT Analysis - Strada, 2016

Table 59: Product Profile - Viotra

Table 60: SWOT Analysis - Viotra, 2015

Table 61: Drugs in Development, 2016

Table 62: Key Events Impacting Sales for MDD Therapies in Japan, 2015-2025

Table 63: MDD Market - Drivers and Barriers in Japan, 2015-2025

Table 64: Key Launch Dates - Part I

Table 65: Key Launch Dates - Part II

Table 66: Key Patent Expiries

Table 67 Average Body Weight and Surface Area Across the 8MM

Table 68: Average Cost of Therapy of Alimta in the 8MM

Table 69: Average Cost of Therapy of Alecensa in the 8MM

Table 70: Average Cost of Therapy of Avastin

Table 71: Average Cost of Therapy of Cyramza

Table 72: Average Cost of Therapy of Gilotrif

Table 73: Average Cost of Therapy of Iressa

Table 74: Average Cost of Therapy of Portrazza

Table 75: Average Cost of Therapy of Tagrisso

Table 76: Average Cost of Therapy of Tarceva

Table 77: Average Cost of Therapy of Vargatef

Table 78: Average Cost of Therapy of Xalkori

Table 79: Average Cost of Therapy of Zykadia

Table 80: Average Cost of Therapy of Keytruda

Table 81: Average Cost of Therapy of Opdivo

Table 82: Average Cost of Therapy of Tecentriq

Table 83: Average Cost of Therapy of Conmana

Table 84: High-Prescribing Physicians Surveyed by Country

List of Figures

Figure 1: Overview of Targets of Antidepressant Action on Noradrenergic and Serotonergic Neurons

Figure 2: Disease Management Model for Major Depressive Disorder

Figure 3: Major Depressive Disorder Treatment Algorithm

Figure 4: MDD Therapeutics - Phase II and III Clinical Trials in the 7MM, 2016

Figure 5: MDD Phase II/Phase III Pipeline, 2016

Figure 6: Competitive Assessment of Late-Stage Pipeline Agents in MDD, 2015-2025

Figure 7: Clinical and Commercial Positioning of ALKS-5461

Figure 8: Clinical and Commercial Positioning of Vraylar

Figure 9: Clinical and Commercial Positioning of ASC-01

Figure 10: Clinical and Commercial Positioning of AXS-05

Figure 11: Clinical and Commercial Positioning of Esketamine

Figure 12: Clinical and Commercial Positioning of Rapastinel

Figure 13: Clinical and Commercial Positioning of Strada

Figure 14: Clinical and Commercial Positioning of Viotra

Figure 15: Japan Sales by Drug Class for MDD Therapies, 2015 and 2025

Figure 16: Japan Sales by Drug Class for MDD Therapies, 2015-2025
Note: Product cover images may vary from those shown
3 of 3


4 of 3
Note: Product cover images may vary from those shown